Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 2Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Metabolic Syndrome 1Hypogonadism 1Fatty Liver 1

Interventions

Zoledronic Acid 15enzalutamide 10Leuprolide 9Goserelin 8bicalutamide 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Triptorelin Pamoate 6Prednisone 6Nivolumab 6Abiraterone Acetate 6luprolide acetate gel depot 5Sunitinib 5Magnetic Resonance Spectroscopy 5Everolimus 5Dutasteride 5Specimen Handling 4Sodium Chloride 4Propofol 4Prednisolone 4Androgen Antagonists 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4pazopanib 3fluciclovine F-18 3darolutamide 3cabazitaxel 3Trimethoprim, Sulfamethoxazole Drug Combination 3Rocuronium 3Mitomycin 3Midazolam 3Flutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Orchiectomy × Genitourinary × Clear all
NCT02102646 2015-10-28

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Herlev Hospital

Phase 4 Completed
31 enrolled
Genitourinary

Fatty Liver, Hypogonadism, Prostatic Neoplasms, Metabolic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡